Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Celecoxib safer than ibuprofen, naproxen in arthritic patients

06 Jan 2018

Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis (OA) and rheumatoid arthritis (RA), a recent study has reported.

The study assessed the relative safety of chronic use of celecoxib vs ibuprofen and naproxen in 24,081 OA or RA patients at moderate or high cardiovascular risk who participated in the PRECISION study, a double-blind randomized controlled trial. Celecoxib was given at 100–200 mg doses twice daily, ibuprofen at 600–800 mg doses three times daily, and naproxen at 375–500 mg doses twice daily.

Primary outcomes investigated were first occurrence of major adverse cardiovascular events (MACE), gastrointestinal events, renal events, and mortality.

In the OA subgroup, celecoxib-treated patients had significantly reduced risk of MACE compared with those who received ibuprofen (hazard ratio [HR], 0.84; 95 percent CI, 0.72–0.99) but not with patients on naproxen. In the RA subgroup, the HR for MACE among celecoxib-treated patients was 1.06 (0.69–1.63) relative to those on ibuprofen and 1.22 (0.78–1.92) relative to those on naproxen.

Cases of gastrointestinal toxicity were also markedly fewer among celecoxib users vs ibuprofen users (HR, 0.68; 0.51–0.91) and naproxen users (HR, 0.73; 0.55–0.98) in the OA subgroup. A similar trend was observed in the RA subgroup, with HRs of 0.48 (0.22–1.07) and 0.54 (0.24–1.24), respectively.

The risk of renal events was substantially lower among celecoxib users vs ibuprofen users in the OA subgroup (HR, 0.58; 0.40­–0.82). Furthermore, celecoxib was associated with significantly lower mortality compared with naproxen in the RA subgroup (HR, 0.47; 0.25–0.88).

“These findings give providers, patients, and regulators a greater understanding of the relative safety of different NSAIDs (nonsteroidal anti-inflammatory drugs), COX2-selective and nonselective,” researchers said, adding that the data confirm no increased CV risk with celecoxib.

“[C]elecoxib conferred slight reductions in risk for several outcomes compared with other commonly used NSAIDs. Regulators and professional organizations might consider whether these data regarding differential safety across NSAIDs warrant new recommendations for the optimal use of the agents studied in PRECISION,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.